Search

Stephen D. Rosasco

Examiner (ID: 4235, Phone: (571)272-1389 , Office: P/1721 )

Most Active Art Unit
1756
Art Unit(s)
1507, 1795, 1721, 1752, 1737, 1756, 1113
Total Applications
2769
Issued Applications
2461
Pending Applications
68
Abandoned Applications
246

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17154952 [patent_doc_number] => 20210316003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY [patent_app_type] => utility [patent_app_number] => 17/206388 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206388 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/206388
BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY Mar 18, 2021 Abandoned
Array ( [id] => 20159301 [patent_doc_number] => 12385922 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Size-based gating to analyze flow cytometry data [patent_app_type] => utility [patent_app_number] => 17/203832 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 7345 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 248 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203832 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/203832
Size-based gating to analyze flow cytometry data Mar 16, 2021 Issued
Array ( [id] => 18272023 [patent_doc_number] => 20230093265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => NEW METHOD AND COMPOUND FOR PROSTATE CANCER DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 17/908291 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908291 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/908291
NEW METHOD AND COMPOUND FOR PROSTATE CANCER DIAGNOSIS Feb 28, 2021 Pending
Array ( [id] => 18452069 [patent_doc_number] => 20230193348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK [patent_app_type] => utility [patent_app_number] => 17/802799 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802799 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/802799
DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK Feb 25, 2021 Pending
Array ( [id] => 17005450 [patent_doc_number] => 20210236611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => COMPOSITION AND PROCESS FOR PREPARING VACCINE [patent_app_type] => utility [patent_app_number] => 17/249362 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249362 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/249362
COMPOSITION AND PROCESS FOR PREPARING VACCINE Feb 25, 2021 Abandoned
Array ( [id] => 17719109 [patent_doc_number] => 20220211828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 17/182886 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17182886 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/182886
TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS Feb 22, 2021 Abandoned
Array ( [id] => 17036706 [patent_doc_number] => 20210253664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => TLR9 LIGAND TRAP [patent_app_type] => utility [patent_app_number] => 17/181246 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181246 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/181246
TLR9 ligand trap Feb 21, 2021 Issued
Array ( [id] => 20264180 [patent_doc_number] => 12435156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Methods for treating neuroblastoma with combination therapy [patent_app_type] => utility [patent_app_number] => 17/181321 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12051 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 248 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181321 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/181321
Methods for treating neuroblastoma with combination therapy Feb 21, 2021 Issued
Array ( [id] => 17052605 [patent_doc_number] => 20210262039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/179956 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17179956 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/179956
Molecular biomarkers for cancer immunotherapy Feb 18, 2021 Issued
Array ( [id] => 17036759 [patent_doc_number] => 20210253717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => Treatment of Patients Having c-Met Exon 14 Skipping Mutations [patent_app_type] => utility [patent_app_number] => 17/174386 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174386 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/174386
Treatment of patients having c-met exon 14 skipping mutations Feb 11, 2021 Issued
Array ( [id] => 18484977 [patent_doc_number] => 20230212292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS [patent_app_type] => utility [patent_app_number] => 17/904098 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904098 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/904098
USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS Feb 9, 2021 Abandoned
Array ( [id] => 17275859 [patent_doc_number] => 20210382057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) [patent_app_type] => utility [patent_app_number] => 17/170769 [patent_app_country] => US [patent_app_date] => 2021-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170769 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/170769
DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) Feb 7, 2021 Abandoned
Array ( [id] => 17200161 [patent_doc_number] => 20210340256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Gene Signatures for Determining ICOS Expression [patent_app_type] => utility [patent_app_number] => 17/168544 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168544 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/168544
Gene Signatures for Determining ICOS Expression Feb 4, 2021 Abandoned
Array ( [id] => 18244326 [patent_doc_number] => 20230076637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/796788 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796788 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/796788
FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME Feb 4, 2021 Pending
Array ( [id] => 20465400 [patent_doc_number] => 12521429 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Zika virus immunogenic compositions [patent_app_type] => utility [patent_app_number] => 17/797662 [patent_app_country] => US [patent_app_date] => 2021-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 47 [patent_no_of_words] => 7316 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797662 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/797662
Zika virus immunogenic compositions Feb 3, 2021 Issued
Array ( [id] => 19296397 [patent_doc_number] => 20240224960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/167578 [patent_app_country] => US [patent_app_date] => 2021-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167578 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/167578
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF Feb 3, 2021 Pending
Array ( [id] => 18240217 [patent_doc_number] => 20230072528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI) [patent_app_type] => utility [patent_app_number] => 17/760202 [patent_app_country] => US [patent_app_date] => 2021-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760202 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/760202
METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI) Feb 3, 2021 Abandoned
Array ( [id] => 16853539 [patent_doc_number] => 20210154284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/165457 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165457 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/165457
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS Feb 1, 2021 Abandoned
Array ( [id] => 17043828 [patent_doc_number] => 11096988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => CD80 variant immunomodulatory proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/161593 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 34 [patent_no_of_words] => 122371 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161593 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/161593
CD80 variant immunomodulatory proteins and uses thereof Jan 27, 2021 Issued
Array ( [id] => 17293460 [patent_doc_number] => 20210389299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => METHODS AND COMPOSITIONS FOR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME TUMORS AND CANCER STEM CELLS [patent_app_type] => utility [patent_app_number] => 17/153198 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153198 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/153198
METHODS AND COMPOSITIONS FOR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME TUMORS AND CANCER STEM CELLS Jan 19, 2021 Abandoned
Menu